Abstract: The invention is in the field of antibodies useful in therapeutic and diagnostics applications targeting CD127, the alpha chain of the IL7 receptor, and provides in particular humanized monoclonal antibodies against CD127, particularly human CD127, therapeutic uses thereof, and diagnostics applications.

Abstract: The present invention relates to anti-CD-25 antibodies for use in the treatment of acute myeloid leukemia (AML) and diffuse large B-cell lymphoma (DLBCL).

Abstract: The present invention relates to the treatment of or alleviation of signs and symptoms of GPP or an acute phase flare-up of generalized pustular psoriasis (GPP) with anti-interleukin-36R (anti-IL36R) antibodies.

Abstract: The present invention relates to combination therapies and to their use in the treatment of chronic airway disease, particularly use in the treatment of asthma. The combination therapies comprise (i) an antagonist of IL-5:IL-5R and (ii) an antagonist of IL-4:IL-4R and/or an antagonist of IL-13:IL-13R. The present invention also provides bispecific antibodies comprising an antigen binding domain that binds to IL-4R? and an antigen binding domain that binds to IL-5. The bispecific antibodies may be used for the treatment of chronic airway disease, particularly asthma.

Abstract: The present application provides a fusion protein, containing: an anti-CD137 antibody capable of specifically binding to a CD137 molecule or an antigen binding fragment thereof; an anti-CD3 antibody capable of specifically binding to a CD3 molecule or an antigen binding fragment thereof; and a first peptide linker and a second peptide linker. The present application also provides a nucleic acid encoding the fusion protein, an expression vector containing the nucleic acid, a host cell containing the nucleic acid or the expression vector, a method for preparing the fusion protein, a pharmaceutical composition containing the fusion protein, and a use of the fusion protein.

Abstract: Methods of treating cancers using a BCMA×CD3 bispecific antibody arc described.

Abstract: This disclosure relates to anti-human OX40 (TNF Receptor Superfamily Member 4, or TNFRSF4) antibodies, antigen-binding fragments, and the uses thereof.

Abstract: It is an object of the present invention to provide an ROS production-enhancing agent. According to the present invention, an ROS production-enhancing agent, comprising a substance that recognizes a transferrin receptor, is provided.

Abstract: Anti-CD73 antibodies are disclosed. Also disclosed are related nucleic acids, vectors, cells, and pharmaceutical compositions. Methods of treating cancer with the anti-CD73 antibodies are also disclosed.

Abstract: The invention relates to antigen-binding polypeptides comprising the CDR1, CDR2 and CDR3 region of a VHH domain of a camelid heavy chain antibody. The polypeptides bind specifically to CD39 and are therefore suitable for the diagnosis as well as for the therapeutic and prophylactic treatment of diseases characterised by increased CD39 expression. Conjugates and pharmaceutical compositions comprising the antigen-binding polypeptides are also disclosed. In addition, the invention relates to the use of such antigen-binding polypeptides in methods for detecting CD39 or CD39-expressing cells in a biological sample. Methods for purifying and concentrating CD39 or CD39-expressing cells using the antigen-binding polypeptides are also described.

Abstract: The present invention relates to therapeutic ADCs comprising SN-38 attached to an anti-Trop-2 antibody or antigen-binding antibody fragment, more particularly sacituzumab govitecan. The ADC is administered to a subject with a Trop-2 positive cancer that is resistant to or relapsed from prior treatment with a checkpoint inhibitor. The therapy is effective to treat cancers that are resistant to checkpoint inhibitors.

Abstract: The present invention relates to therapeutic ADCs comprising SN-38 attached to an anti-Trop-2 antibody or antigen-binding antibody fragment, more particularly sacituzumab govitecan. The ADC is administered to a subject with a Trop-2 positive cancer that is resistant to or relapsed from prior treatment with a checkpoint inhibitor. The therapy is effective to treat cancers that are resistant to checkpoint inhibitors.

Abstract: The present invention relates to therapeutic ADCs comprising SN-38 attached to an anti-Trop-2 antibody or antigen-binding antibody fragment, more particularly sacituzumab govitecan. The ADC is administered to a subject with a Trop-2 positive cancer that is resistant to or relapsed from prior treatment with a checkpoint inhibitor. The therapy is effective to treat cancers that are resistant to checkpoint inhibitors.

Abstract: The present invention relates to therapeutic ADCs comprising SN-38 attached to an anti-Trop-2 antibody or antigen-binding antibody fragment, more particularly sacituzumab govitecan. The ADC is administered to a subject with a Trop-2 positive cancer that is resistant to or relapsed from prior treatment with a checkpoint inhibitor. The therapy is effective to treat cancers that are resistant to checkpoint inhibitors.

Abstract: The present application discloses a method of determining suitability of treating a patient suffering from cancer or metastasis of cancer characterized by aberrant expression of MUC1, with a MUC1* targeting therapeutic.

Abstract: A nanobody or an antigen-binding fragment thereof against a specific region of a factor XII (FXII) is provided. The nanobody or the antigen-binding fragment thereof binds to FXII through a binding epitope for FXII to block the activation of FXII, and the binding epitope for FXII includes a conformational epitope. A neutralizing antibody for FXII screened by phage display is provided, and it has been found that the neutralizing antibody can treat thrombosis, myocardial ischemia-reperfusion injury (IRI), and vasculitis in mouse arterial thrombosis, rat extracorporeal membrane oxygenation (ECMO), mouse IRI, and vasculitis models.

Abstract: Masked chimeric antigen receptor (CAR) constructs comprising an extracellular antigen binding domain specific tyrosine-protein kinase-like 7 (PTK7), which is linked to a mask peptide that blocks binding of masked CAR from binding to PTK7. Also provided herein are genetically engineered T cells expressing a masked CAR specific to PTK7 and therapeutic uses thereof.

Abstract: In one aspect, the present invention provides methods for preventing, treating, reverting and/or delaying angiogenesis in a mammalian subject suffering from, or at risk for developing, an angiogenesis-dependent disease or condition, comprising administering to the subject an amount of a MASP-2 inhibitory agent effective to inhibit angiogenesis. In some embodiments of these aspects of the invention, the MASP-2 inhibitory agent is a MASP-2 antibody or fragment thereof.

Abstract: A pharmaceutical composition comprising an anti-TIGIT antibody or an antigen-binding fragment thereof, and an anti-CTLA4-anti-PD-1 bispecific antibody or an antigen-binding fragment thereof. Specifically, a heavy chain variable region of the antibody contains HCDR1-HCDR3 having amino acid sequences as shown in SEQ ID NOs: 3-5, respectively, and a light chain variable region contains LCDR1-LCDR3 having amino acid sequences as shown in SEQ ID NOs: 8-10, respectively.

Abstract: Described herein are compositions (e.g. cells and transgenic animals) and methods relating to engineered Ig loci that permit expression of particular antibodies or antibody segments while still permitting recombination and/or maturation process for antibody optimization.

Abstract: Disclosed herein are novel bispecific and tri-specific antibodies with increased stability and use thereof for therapy.

Abstract: Described herein is a composite binding molecule, wherein the composite binding molecule comprises a (i) CD38 antigen binding component that binds CD38, (ii) a CD19 antigen binding component that binds CD19, and (iii) a variant Fc region comprising one or more mutations relative to a wildtype Fc region, wherein the variant Fc region exhibits reduced effector function compared to the wildtype Fc region. Also described are methods of using the composite binding molecule in a method of treating cancer.

Abstract: It is provided a method and composition of chitosan, where the chitosan, independent of its molecular weight or degree of deacetylation, is dissolved in an acid free aqueous solution comprising charged aldehyde without the need of protonating agent, and wherein amino groups of chitosan form imine bonds with the aldehyde functions of the acid free aqueous solution making chitosan hydrophilic with negatively charged chains and resulting in chitosan particles being entrained in solution producing a acid free chitosan composition.

Abstract: Hyaluronic acid compositions comprised of precipitated and stabilized hyaluronic acid are disclosed. The compositions may enable higher doses and half-lives of hyaluronic acid delivered in tissues throughout the body to prolong therapeutic effects through controlled solubilization of hyaluronic acid. Compositions may include networks of hyaluronic acid (HA). The networks may provide enhanced control of HA hydration and swelling to increase the amount of exogenous HA that can be delivered into the body and extend the duration of exogenously delivered HA in the body.

Abstract: The invention relates to a process for preparing polyalpha-olefins using a catalyst composition comprising a reaction product of an organometallic complex and a co-catalyst, wherein the comprising an organometallic complex is represented by the general formula: LMXn wherein: (i) ‘L’ is an organic ligand; (ii) ‘M’ is a transition metal having a valency of ‘p’, wherein the metal ‘M’ is selected from Ti, Zr, and Hf; (iii) ‘X’ is an anionic ligand to the metal ‘M’, and wherein ‘X’ is selected from the group consisting of halogens, alkyls, aralkyls, alkoxides, amides, and combinations thereof; (iv) ‘n’ is the number of ‘X’ groups and equals p-2.

Abstract: The present invention relates to a material, in particular a fluorocarbon polymer, functionalized by an aliphatic polyamine selected from aliphatic diamines having two primary amines and aliphatic triamines having two or three primary amines, or by a phosphoramide, to the method for preparing same and to the uses thereof. The invention also relates to the use of a composition of an alkali metal and such an aliphatic polyamine for the preparation of a material, in particular a fluorocarbon polymer, which is functionalized.

Abstract: A a crosslinkable polymer composition which provides a crosslinked product capable of both heat resistance and re-formability, a crosslinked polymer material capable of both heat resistance and re-formability, and an insulated wire and a wiring harness including the crosslinked polymer material. The crosslinkable polymer composition includes: ingredient A from which metal ion is released by heat; and ingredient B including an organic polymer having a side chain, including an electron-withdrawing substituent group capable of forming an ionic bond with the metal ion, and when B is crosslinked via the metal ion to form a crosslinked product, the product has a flow starting temperature of 190° C. or higher and 300° C. or lower. The crosslinked polymer material includes the crosslinked product of the crosslinkable polymer composition. The insulated wire includes a wire conductor, and an insulation coating including the crosslinked polymer material, and the wiring harness including the insulated wire.

Abstract: Provided is a process for the polymerization of ethylene comprising introducing ethylene, a liquid light hydrocarbon diluent, at least one catalyst, at least one cocatalyst, and optionally one or more comonomers into a reactor; polymerizing the ethylene and optionally the one or more comonomers in the reactor to produce an ethylene polymer; wherein the reactor is fluidly connected to a cooling system, the cooling system comprising a slurry-free heat exchanger, and the cooling system is configured to receive a vapor stream comprising light hydrocarbon vapor produced in the reactor. Also provided is an ethylene polymer produced from the process for polymerizing ethylene and a system for producing an ethylene polymer.

Abstract: Disclosed is a preparation method for a polytrifluorostyrene. The method comprises: (i) providing a pre-emulsion of a trifluorostyrene monomer and a non-perfluorinated fluorine-containing anionic surfactant, wherein based on the weight of the trifluorostyrene monomer, the amount of the non-perfluorinated fluorine-containing anionic surfactant in the emulsion is 0.1-5 wt %, the non-perfluorinated fluorine-containing anionic surfactant has the general formula: CF3(CFX)n-(CH2)m-(C6H4)o-M, where n is an integer of 1-7, m is an integer of 1-4, and o is an integer of 0-2; X is selected from —F, —CF3, —OCF3, and —FCF2C(CF3)2; and M is selected from a carboxyl group, a sulfo group or respective salts thereof; (ii) adding an initiator to initiate a microemulsion polymerization reaction of the trifluorostyrene monomer; and (iii) adding a coagulant for demulsification.

Abstract: To provide a branched propylene-based polymer that is excellent in ductility when melting, while retaining melt tension necessary for molding. A branched propylene-based polymer having the following properties (1), (2) and (3): property (1): a multi-branching index (MBI) is 0.45 or more and 1.00 or less; property (2): a strain hardening index at a strain rate (d?/dt) of 1.0/see (SHI@1s?1) is 0.70 or more and 3.00 or less; and property (3): a maximum drawing rate (MaxDraw) at 230° C.

Abstract: A propylene ethylene copolymer having: i) a xylene soluble fraction at 25° C. ranging from 30 wt % to 48 wt %; ii) an intrinsic viscosity of the xylene soluble fraction, ranging from 2.8 to 4.3 dl/g; iii) a melt flow rate, measured according to ISO 1133 at 230° C. with a load of 2.16 kg, ranging from 0.2 g/10 min to 10 g/10 min; iv) an ethylene derived units content ranging from 10.3 wt % to 15.4 wt %; v) the ethylene derived units content on the xylene insoluble fraction, ranging from 6.1 wt % to 9.0 wt %; vi) the ethylene derived units content on the xylene soluble fraction, ranging from 18.2. wt % to 30.2 wt %; vii) the 13C-NMR sequences PEP measured on the xylene insoluble fraction, ranging from 4.1 mol % to 6.5 mol %; and (viii) the 13C-NMR sequences PEP measured on the xylene soluble fraction, ranging from 10.5 mol % to 14.2 mol %.

Abstract: A vinyl acetate-ethylene (VAE) copolymer and uses of the same are provided. The vinyl acetate-ethylene (VAE) copolymer includes a structural unit derived from ethylene and a structural unit derived from vinyl acetate. The 1H-NMR spectrum of the vinyl acetate-ethylene (VAE) copolymer has an integral value B of signals from 0.5 ppm to 1.0 ppm and an integral value A of signals from 4.6 ppm to 5.0 ppm, and the value of B/3A ranges from 0.070 to 0.120. The 1H-NMR spectrum is measured by using dimethyl sulfoxide as a solvent.

Abstract: A polymer represented by the formula (1) is provided. in which RA1 and RA2 have the meanings as defined in the claims and the description. X represents a phenylene group, an ethylene group, or a phenylenevinylene group, RD1 and RD2 have the meanings as defined in the claims and the description. Y represents a linking group. Po represents a polymer structure.

Abstract: The present invention relates to a copolymer and core-shell particles, a slurry composition, a separator and a secondary battery which comprise the copolymer, the copolymer comprising, with respect to 100 wt % of the total weight of the copolymer, greater than 5 wt % and less than or equal to 70 wt % of an acrylonitrile-based monomer unit, greater than or equal to 15 wt % and less than 90 wt % of an acrylate-based monomer unit, 1-20 wt % of an acrylamide-based monomer unit, and 1-10 wt % of an acrylic acid-based monomer unit.

Abstract: The present invention relates to a resin composition comprising: a polymer (I) selected from the group consisting of a polymer (a1) containing a structural unit (i) having an ester linkage type betaine structure and a polymer (b1) containing a structural unit (ii) having a betaine structure that is not of an ester linkage type and a structural unit (iii) having a carboxyl group; an organic solvent having a Hansen solubility parameter at 25° C. in which a dispersion term ?D is 10 to 24 MPa1/2, a polarity term ?P is 5 to 19 MPa1/2, and a hydrogen bonding term ?H is 3 to 17 MPa1/2, and having a boiling point higher than 100° C.; and water.

Abstract: A rigid gas permeable prepolymer comprising a reaction product of (a) a rigid gas permeable-forming prepolymer comprising (i) monomeric units derived from a bulky siloxane monomer containing an ethylenically unsaturated reactive end group, and (ii) monomeric units derived from a hydrophilic monomer having one or more reactive functionalities and an ethylenically unsaturated reactive end group, and (b) a monomer having a reactive functionality complementary to one of the one or more reactive functionalities of the hydrophilic monomer and a polymerizable ethylenically unsaturated reactive end group complementary to an ethylenically unsaturated reactive group of a rigid gas permeable contact lens-forming comonomer. Rigid gas permeable contact lenses formed from the rigid gas permeable prepolymers are also disclosed.

Abstract: An object is to provide a polydimethylsiloxane-containing monomer that exhibits satisfactory compatibility with a hydrophilic monomer and a hydrophilic polymer, in which a polymerization product obtained by polymerizing a composition including the polydimethylsiloxane-containing monomer, the hydrophilic monomer, and the hydrophilic polymer has an anti-lipid adhesion property. It has been recognized that a polydimethylsiloxane-containing monomer having a phosphorylcholine group and a hydroxy group can achieve the object, and thus the present disclosure has been completed.

Abstract: A liquid radiation curable composition comprising component a) 20 to 60 weight percent of one or more reactive oligomer(s) containing at least two urethane and/or urea linkages in the backbone and at least two ethylenic unsaturated group(s) which can form polymeric crosslink networks with the other components in the composition in the presence of radicals, anions, nucleophiles or combinations thereof, with a weight average molecular weight (Mw) of greater than 3000 g/mol and glass transition temperature Tg of the cured reactive oligomer(s) itself is greater than 25° C.

Abstract: An image display device including an image display panel and a front panel that are laminated via a transparent resin layer, when a photocurable material for forming the transparent resin layer is used as a dam agent or a fill agent, the photocurable material includes a component (a), which is a (meth)acrylic acid ester component; a component (b), which is a plasticizer component; and a component (c), which is a photopolymerization initiator component in order to make it difficult to visually recognize a knit line between the dam portion and the fill portion of the transparent resin layer after curing. A difference between the refractive index of the photocured product of the component (a), which is the (meth)acrylic acid ester component and the refractive index of the plasticizer component as the component (b) is 0.02 or less.

Abstract: The present disclosure provides cross-linker compounds that can produce desirable polymeric materials, polymer compositions, and/or photo-curable resins. Further provided herein are methods of producing cross-linker compounds, compositions, resins, devices, and polymeric materials. Also provided herein are methods of using cross-linker compounds, resins, and polymeric materials for the fabrication (e.g., via 3D printing) of medical devices, such as orthodontic appliances.

Abstract: Provided are a chloroprene-based block copolymer, a latex, a latex composition, and a rubber composition with which it is possible to obtain a molded body having excellent tensile strength at break and tensile elongation at break even with use of less or no vulcanizing agent or vulcanization accelerator. A chloroprene-based block copolymer including 30 to 60% by mass of a polymer block (A) derived from a monomer that can yield a polymer with a glass transition temperature of 80° C. or higher when homopolymerized and 40 to 70% by mass of a chloroprene-based polymer block (B) having a chloroprene monomer unit and a polyfunctional monomer unit.

Abstract: A multiblock copolymer having a structure in which polystyrene chains are attached to both terminals of a polyolefin chain, a resin composition comprising same, and methods for preparing them are described herein.

Abstract: A curable composition containing piezoelectric particles and a compound represented by the following formula (1): wherein R11 and R12 each independently represent a hydrogen atom or a methyl group, and R13 represents a divalent group having a polyoxyalkylene chain.

Abstract: The present invention relates to an aqueous polyurethane dispersion comprising: a polyurethane A having pendant acid salt groups and end-standing carbonyl groups, and optionally a multifunctional compound B having functional groups reactable with the carbonyl groups of polyurethane A. The present invention further relates to a method for producing said aqueous polyurethane dispersion and to a coating comprising said aqueous polyurethane dispersion.

Abstract: The present disclosure provides curable compositions comprising one or more of photo-polymerizable urethane prepolymers having alternating hard and soft blocks, as well as polymeric materials formed from the curable compositions. Further provided herein are methods of producing the compositions and using the same for the fabrication of medical devices, such as orthodontic appliances.

Abstract: An object of the present invention is to provide a binder resin composition having excellent storage stability and jettability of the composition and being capable of providing excellent abrasion resistance and color development properties of printed materials. A binder resin composition for aqueous ink-jet ink applications of the present invention includes a urethane resin (I), a basic compound (II), and an aqueous medium (III). The urethane resin (I) is a reaction product of a polyol (a), a polyisocyanate (b), and an amine compound (c). The amine compound (c) is a plurality of amine compounds having different structures, and one of the amine compounds is a linear diamine compound (c1-1) or a hydrazine compound (c1-2).

Abstract: The present application relates to a composition comprising some components; using thereof; manufacturing a layer; and manufacturing an electronic device.

Abstract: Provided herein are a polymer resin and a polymer network. The polymer resin includes at least one cyclopolymerized ortho-diynylarene (ODA) monomer and is processable at a temperature of less than 200° C. The polymer network includes a network formed from the polymer resin.

Abstract: Disclosed herein are electrically conductive polymer compositions comprising a polymer and a dispersant, and methods of synthesizing the polymers therein. Also disclosed herein are microelectrode arrays comprising the electrically conductive material and a conductive polymer composition attached to a surface of the electrically conductive material. Further disclosed herein are methods of detecting electrical activity in a cell comprising contacting the microelectrode array with a cell and detecting electrical activity in the cell by covalently attaching the polymer of the conductive polymer composition to a protein on the surface of the cell.

Abstract: A poly(glycolic acid)-containing resin composition includes a poly(glycolic acid), a zinc-containing ionomer (Zn ionomer), and an ethylene-based terpolymer. A film including the poly(glycolic acid)-containing resin composition is also provided. The poly(glycolic acid)-containing resin composition and the film can be widely applied in the field of green technologies, such as a biodegradable resin, a biodegradable food packaging film, a biodegradable sanitary product, and other biodegradable plastics.